Pharmacogenetic-Guided Treatment for Depression
(ADOPT PGx Trial)

Recruiting in Palo Alto (17 mi)

+12 other locations

Overseen byJosh F. Peterson, MD

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Duke University

No Placebo Group

Trial Summary

What is the purpose of this trial?This trial helps doctors choose the best treatment for patients with depression by understanding how their bodies process medication, potentially improving symptoms more quickly.

Eligibility Criteria

This trial is for English or Spanish speakers aged 8 years and above with depression, who are starting or changing SSRI therapy at participating clinics. They must have had depressive symptoms for at least 3 months. Excluded are those too ill to consent, planning to move soon, with bipolar disorder, seizure disorders, certain genetic test results, psychosis, dementia or cognitive disabilities.

Inclusion Criteria

I have been diagnosed with depression.

I am 8 years old or older.

Patients followed at psychiatry clinics or primary care clinics at an enrolling site (such as, but not limited to, Internal Medicine, Family Medicine, or Pediatrics)

+3 more

Exclusion Criteria

I am unable to understand or follow the study's procedures due to cognitive issues.

Have cognitive developmental delay and/or cognitive disability, including autism spectrum disorders (Note: ADHD is not an exclusion criteria)

I have a condition that causes seizures.

+8 more

Participant Groups

The Depression Trial compares immediate pharmacogenetic testing and tailored anti-depressant therapy against standard care with delayed testing. It aims to see if personalized treatment based on how a person's body processes SSRIs can better reduce depression symptoms.

2Treatment groups

Experimental Treatment

Group I: Depression - Immediate PGx TestingExperimental Treatment2 Interventions

Immediate genetic testing of CYP2D6 and CYP2C19 and clinical decisions support for antidepressant prescribing to the healthcare provider

Group II: Depression - Delayed PGx TestingExperimental Treatment1 Intervention

Delayed genetic testing of CYP2D6 and CYP2C19 and return of results after the conclusion of the 6-month follow-up period